Skip links

Sorrento’s Predatory Propaganda

May 20, 2020 – Sorrento Therapeutics’ announcement of Covid-19 “cure” follows management’s long history of unsuccessfully tailgating fads while squandering hundreds of millions in fresh investment capital.

Viceroy Research are short Sorrento Therapeutics (NASDAQ:SRNE) – a biotech company with wild claims it has basically found the cure for SARS-Cov-2 (Covid-19) amid a history of apparent stock pumping by its management team and transaction advisors. We believe Sorrento deliberately rides the pandemic wave for the sole purpose of pumping its stock price, with a propaganda machine to match.

Amid these COVID-19-related announcements, Sorrento have executed a new share sale prospectus for $250m of shares at VWAP to capitalize on the destruction of the pandemic. This will be the single largest value deal for sale agent Alliance Global Partners (AGP). AGP has uncanny propensity to flood capital markets with garbage.

Sorrento has virtually no revenue and has burnt through over $420m of cash over the last 3 years at an increasing rate. Sorrento has failed to significantly monetise any of its assets and seems to exist solely to raise billions in capital from equity and debt markets. Their development catalogue is extremely varied with several product stalled in clinical testing or R&D.

Part of this cash burn and asset stripping has been called into question in the past from major shareholder Wildcat Capital Management.

Given Sorrento’s lengthy history of false promises and bad company, Viceroy doubts management can coerce investors into burning cash once more, and the company will fizzle out of existence.

Important Disclaimer – Please read and acknowledge before continuing

Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.

Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.

To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.

In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.

This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.

Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.

You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.

The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.